Vivo Capital

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

35Pharma is a biopharmaceutical company that designs and develops innovative biologics to address diseases with high unmet medical need. The company applies protein engineering and a deep understanding of transforming growth factor-beta structure-function relationships to create potent ligand traps for cardio-pulmonary and metabolic diseases, including pulmonary hypertension and musculoskeletal disorders.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Serán Bioscience is a contract development and manufacturing organization that specializes in providing a wide range of services to pharmaceutical and biotechnology companies. The company offers a comprehensive suite of development, analytical, and clinical manufacturing services, aimed at optimizing drug development and production processes. By catering to various aspects of pharmaceutical development, Serán Bioscience supports its clients in efficiently bringing their products to market.

Celcuity is a clinical-stage biotechnology company that discovers new cancer sub-types and therapeutic options using its proprietary CELsignia diagnostic platform. This platform analyzes living tumor cells to identify specific abnormal cellular processes driving cancer, enabling the development of targeted therapies for patients.

Ajax Therapeutics is a New York City-based biotechnology company that applies computational chemistry and structure-based technologies to develop novel small molecules for treating hematologic malignancies.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy-based treatments for severe and life-threatening rare genetic diseases. Its pipeline includes therapies for Sanfilippo syndrome types A and B, epidermolysis bullosa, Batten disease, cystic fibrosis, and genetic eye disorders.

Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

Adverum Biotechnologies is a clinical-stage company focused on developing gene therapies to treat ocular diseases. Its pipeline includes ADVM-022 for wet age-related macular degeneration, ADVM-043 for alpha-1 antitrypsin deficiency, and preclinical candidates for other indications.

Silence Therapeutics is a London-based biotechnology company that develops RNA therapeutics using short interfering RNA to trigger RNA interference and degrade disease-causing messenger RNA. It focuses on discovery, development, and delivery of siRNA medicines for hematology, cardiovascular disease, and other rare and metabolic conditions. The company has a proprietary mRNAi GOLD platform to create internal candidates and collaborates on out-licensed programs, including a strategic partnership with AstraZeneca to discover, develop, and commercialize siRNA therapies across cardiovascular, renal, metabolic, and respiratory indications, as well as a collaboration with Genomics England. Its product candidates include SLN124 for iron overload, SLN360 for cardiovascular disease associated with high lipoprotein, and SLN500 for complement-mediated diseases. Silence Therapeutics also pursues delivery systems for targeting multiple organs and cell types, supporting a pipeline across its three focus areas.

BlossomHill Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for oncology and autoimmune diseases. It specializes in small molecule drug discovery, leveraging advanced drug design expertise and precision medicine approaches.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

COMPASS Pathways is a UK-based mental health care company dedicated to accelerating patient access to innovative treatments for mental health challenges. The company focuses on developing psilocybin therapy, administered in conjunction with psychological support, for patients with treatment-resistant depression who have not responded to conventional treatments.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Bonum Therapeutics is a biotechnology company focused on developing protein-based drugs aimed at treating various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs capable of sensing their local environment and transitioning from an inactive to an active form. This innovative approach allows for the development of therapeutics that can be tailored to respond to specific conditions, thereby enhancing the potential for effective treatment of diseases that currently lack viable cures. In addition to cancer, Bonum Therapeutics also targets metabolic diseases, immunological disorders, and pain management.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Inspirna is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer therapies that target RNA-regulated drivers of tumor growth. Using RNA biology-based discovery platforms, including miRNA-DRIVEr and RNA-DRIVEr, it identifies novel cancer targets and advances them with oral small-molecule medicines and antibody-drug conjugates. Its lead programs include RGX-202 for RAS-mutant colorectal cancer and RGX-104 for small cell and non-small cell lung cancers, currently in early-phase trials (Phase 1b/2). The company aims to translate RNA-centric targets into treatments for patients with cancers that lack effective options.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, delivering biologically active compounds to the immune system through the skin using its Viaskin platform. Its lead product candidate, Viaskin Peanut, targets peanut allergy and is advancing for use in children aged 4 to 11 and other age groups. The company is developing Viaskin Milk for immunotherapy of cow’s milk protein allergy and milk-induced eosinophilic esophagitis, Viaskin Egg in preclinical development for egg allergy, and a booster vaccine for Bordetella pertussis. Additional early-stage programs include efforts against respiratory syncytial virus, Crohn’s disease, celiac disease, and type 1 diabetes. DBV Technologies has collaborations to expand its diagnostic capabilities, including a patch-based test with Nestlé Health Science for non-IgE mediated CMPA. Founded in 2002 and headquartered in Montrouge, France, the company emphasizes skin-delivered immunotherapy as its core approach.

Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing Targeted Radiotherapy (TRT) treatments aimed at benefiting cancer patients. The company focuses on innovative TRT products, utilizing the extensive business experience and networks of its founders in cross-border product development and deal-making. By targeting the Chinese market, Ablaze Pharmaceuticals seeks to provide effective cancer treatment options tailored to the needs of patients in the region.

Histowiz is a biotechnology company established in 2012, specializing in histology services for cancer researchers. It processes, embeds, cuts, stains, and digitizes mouse tissue specimens, offering automated pathology solutions to academia and pharmaceutical clients.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company based in Campbell, California, focused on developing innovative therapies for gastrointestinal disorders. Incorporated in 2017, the company specializes in creating products that address unmet medical needs related to the enteric nervous system. One of its lead products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx aims to provide effective solutions for functional and motility gastrointestinal disorders, targeting issues related to gut contractions, sensation, and the brain-gut axis, thereby addressing significant patient needs and alleviating disease burdens.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Larimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. Its lead compound, CTI-1601, is currently in Phase 1 clinical trials as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.

Sera Prognostics, Inc. is a biotechnology company that develops diagnostic tests to predict a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy complications. Using proteomics and bioinformatics, it discovers and commercializes blood-based biomarker tests and predictive analytics to guide early, personalized interventions and reduce healthcare costs associated with pregnancy complications. Founded in 2008 and based in Salt Lake City, Utah, Sera aims to improve maternal and neonatal outcomes by providing physicians with actionable risk information during pregnancy.

Lepu Biotechnology Co., Ltd. is a Chinese biotech company specializing in tumor immunotherapy. Founded in 2018, it has developed an industrial platform dedicated to target discovery, drug preparation, development, and manufacturing. The company focuses on creating drug candidates that include programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies, an oncolytic virus, and various antibody-drug conjugates (ADCs). Lepu Bio's core products are currently in clinical stages I to III, demonstrating its commitment to advancing cancer treatment through innovative biopharmaceutical solutions.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

BlossomHill Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for oncology and autoimmune diseases. It specializes in small molecule drug discovery, leveraging advanced drug design expertise and precision medicine approaches.

ASLAN Pharmaceuticals, established in 2010 and based in Singapore, is a clinical-stage biopharmaceutical company focused on immunology and oncology. It develops innovative treatments, including a monoclonal therapy for atopic dermatitis and a small molecule inhibitor for cancer, aiming to transform patients' lives. The company collaborates with prominent pharmaceutical partners and operates as a subsidiary of ASLAN Pharmaceuticals Limited.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Design Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Solana Beach, California, focused on developing innovative therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company specializes in a novel class of small-molecule gene-targeted chimera therapeutics known as GeneTACTM molecules, which aim to modify disease progression by addressing the root causes of these conditions. Its lead program targets Friedreich’s ataxia, while additional efforts are directed toward conditions such as Fuchs endothelial corneal dystrophy and other degenerative diseases like Fragile X syndrome and myotonic dystrophy. Since its incorporation in 2017, Design Therapeutics has been dedicated to advancing its therapeutic candidates to potentially transform treatment options for patients suffering from these inherited disorders.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Serán Bioscience is a contract development and manufacturing organization that specializes in providing a wide range of services to pharmaceutical and biotechnology companies. The company offers a comprehensive suite of development, analytical, and clinical manufacturing services, aimed at optimizing drug development and production processes. By catering to various aspects of pharmaceutical development, Serán Bioscience supports its clients in efficiently bringing their products to market.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

Serán Bioscience is a contract development and manufacturing organization that specializes in providing a wide range of services to pharmaceutical and biotechnology companies. The company offers a comprehensive suite of development, analytical, and clinical manufacturing services, aimed at optimizing drug development and production processes. By catering to various aspects of pharmaceutical development, Serán Bioscience supports its clients in efficiently bringing their products to market.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Provivi Inc. is a biotechnology company based in Santa Monica, California, focused on the development of biopesticides for agricultural, commercial, household, and public health pest management. Founded in 2013, the company leverages biocatalysis technology, originally developed at the California Institute of Technology, to create insect pheromones that protect food supplies without toxic residues. Provivi aims to provide effective and environmentally friendly crop protection solutions, fostering sustainable agricultural practices. Its innovative approach targets the synthesis of biopesticides through advanced processes, allowing for the efficient production of safe and affordable pest management products. The company distributes its offerings worldwide, seeking to transform pest control with its groundbreaking biological solutions.

Elevation Oncology develops precision medicines for genomically defined cancers. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions, currently in Phase 2 trials.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic respiratory diseases with unmet medical needs. Its lead candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterases 3 and 4 that provides bronchodilation and anti-inflammatory effects in a single molecule. Development programs include formulations of ensifentrine for chronic obstructive pulmonary disease, with options such as nebulized administration, a dry powder inhaler, and a pressurized metered-dose inhaler. Verona Pharma is also pursuing development of ensifentrine for cystic fibrosis and asthma. The company was founded in 2005 and is headquartered in London, United Kingdom.

Tranquis Therapeutics is a biotechnology company developing innovative immuno-therapeutics targeting myeloid immune cell dysfunction linked to various neurodegenerative and aging-related disorders. Its lead candidate, TQS-168, has shown promising results in preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment.

Bolt Biotherapeutics is a biotechnology company developing cancer immunotherapies based on the Boltbody platform, which links tumor-targeting antibodies to immune-stimulating payloads to activate innate and adaptive immune responses against solid tumors. The platform aims to transform non-responsive, or cold, tumors into immunologically active ones by delivering immune stimulants at the tumor site. The company’s pipeline includes BDC-1001 as a monotherapy for HER2-expressing solid tumors, with additional candidates such as BDC-3042 and Next-Gen ISAC designed to broaden its immuno-oncology program. Bolt Biotherapeutics focuses on myeloid biology and tumor-targeted therapies to leverage immune mechanisms for cancer treatment.

Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.

Legend Biotech is a clinical-stage biopharmaceutical company focused on discovering and developing novel cell therapies for oncology and other indications. Its lead candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T therapy for multiple myeloma, evaluated in various trials including earlier-line settings and comparisons with standard therapies in Revlimid-refractory disease. The company also has a broad pipeline of autologous and allogeneic CAR-T and related immunotherapies targeting solid tumors and hematologic cancers, including investigations into CD20-directed allogeneic CAR-T for non-Hodgkin lymphoma in China as an investigator-initiated Phase 1 study, as well as early preclinical and clinical programs for additional cancers and infectious diseases. Legend Biotech was founded in 2014 and is based in Somerset, New Jersey; it is a subsidiary of Genscript Biotech Corporation.

Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Aligos Therapeutics is a biopharmaceutical company dedicated to developing innovative therapeutics targeting viral infections and liver diseases. Founded in 2018, the company focuses on chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH), leveraging its expertise in liver disease drug development.

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for ophthalmic conditions, with a pipeline that includes first-in-class candidates aimed at Demodex blepharitis and other eye diseases. Its lead program, TP-03, targets blepharitis caused by Demodex mites and is advancing through Phase IIb/III trials, alongside efforts to address meibomian gland disease. The company is also developing TP-04 for rosacea and TP-05 for Lyme prophylaxis and community malaria reduction, indicating a broader dermatology and infectious-disease focus. Tarsus pursues development across opportunities with unmet medical need, aiming to bring novel therapeutics to patients with limited treatment options. The company was founded in 2016 and is headquartered in Irvine, California.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit difficult growth and survival pathways, with an emphasis on RAS and mTOR signaling. Its portfolio includes RMC-4630, a SHP2 inhibitor, and programs addressing RAS-driven signaling via SOS1 and downstream 4EBP1/mTORC1 pathways. The company pursues a chemistry-based approach that assembles simple building blocks into drug-like, natural product-inspired structures, aiming to produce best-in-class candidates. It operates in collaboration with academic partners, including a licensing arrangement with the University of Illinois to extend its transformative synthesis technology, which underpins its drug discovery platform.

IGM Biosciences, Inc. is a biotechnology company that specializes in the research and development of engineered Immunoglobulin M (IgM) antibodies aimed at treating cancer and other diseases. The company’s lead product candidate, IGM-2323, is a bispecific IgM antibody currently undergoing Phase 1 clinical trials for the treatment of relapsed or refractory B cell Non-Hodgkin's lymphoma. In addition, IGM is developing IGM-8444, an IgM antibody targeting Death Receptor 5 for solid and hematologic malignancies, and IGM-7354, a bispecific IgM antibody designed to deliver interleukin-15 cytokines to PD-L1 expressing cells. IGM Biosciences has established collaborations focused on the discovery and development of novel IgM and IgA antibodies, including partnerships for potential COVID-19 treatments. Founded in 1993 and headquartered in Mountain View, California, the company was previously known as Palingen, Inc. and adopted its current name in 2010.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

Bolt Biotherapeutics is a biotechnology company developing cancer immunotherapies based on the Boltbody platform, which links tumor-targeting antibodies to immune-stimulating payloads to activate innate and adaptive immune responses against solid tumors. The platform aims to transform non-responsive, or cold, tumors into immunologically active ones by delivering immune stimulants at the tumor site. The company’s pipeline includes BDC-1001 as a monotherapy for HER2-expressing solid tumors, with additional candidates such as BDC-3042 and Next-Gen ISAC designed to broaden its immuno-oncology program. Bolt Biotherapeutics focuses on myeloid biology and tumor-targeted therapies to leverage immune mechanisms for cancer treatment.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Impel Pharmaceuticals is a late-stage pharmaceutical company focused on developing transformative therapies using its proprietary Precision Olfactory Delivery (POD) system. The company's pipeline includes TRUDHESA™ for migraine treatment, INP105 for autism-related agitation, and INP107 for Parkinson's disease OFF episodes.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Tot Biopharm is a clinical-stage biopharmaceutical company based in Suzhou, China. Founded in 2010, it specializes in developing and commercializing innovative oncology drugs and therapies. Tot Biopharm's flagship product is S-1, an oral antineoplastic drug that provides oral delivery of 5-FU, enhancing its efficacy while reducing gastrointestinal toxicity.

Sinovac Biotech Ltd., established in 1999 and headquartered in Beijing, China, is a biopharmaceutical company dedicated to the research, development, manufacture, and commercialization of vaccines against human infectious diseases. Its portfolio includes vaccines for hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and hand, foot, and mouth diseases. Notable products include Healive for hepatitis A, Bilive for combined hepatitis A and B, Anflu for seasonal influenza, Panflu for H5N1 influenza, Panflu.1 for H1N1 influenza, and Inlive for EV71. The company has completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines and is advancing trials for other vaccines such as Sabin inactivated polio, pneumococcal conjugate, rubella, and quadrivalent influenza. Sinovac collaborates with GlaxoSmithKline Biologicals SA and Tianjin CanSino Biotechnology Inc. for vaccine development. The company primarily sells its vaccines in China and exports to select countries including Mongolia, Nepal, and the Philippines.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.